Essex Investment Management’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Essex Investment Management’s Portfolio VIRX Stock Details VIRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-1,690	Closed	-$2.53M	–	361
2014 Q3	$2.53M	Buy	1,690 +1,135	+205%	+$1.64M	0.39%	73
2014 Q2	$760K	Sell	555 -344	-38%	-$399K	0.11%	211
2014 Q1	$1.25M	Sell	899 -14	-2%	-$16.3K	0.18%	172
2013 Q4	$909K	Buy	913 +710	+350%	+$734K	0.13%	206
2013 Q3	$211K	Buy	+203	New	+$217K	0.03%	331

Other funds holding VIRX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return

Essex Investment Management's VIRX Position: Q4 2014 in Review

Essex Investment Management sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q4 2014, closing a stake of 1,690 shares — an estimated $2.53M sold.

Essex Investment Management first reported a position in VIRX in Q3 2013 and held it in 5 quarters. The position peaked at $2.53M in Q3 2014. 78 funds tracked by Wall St. Rank hold VIRX as of Q4 2014.

Essex Investment Management reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q4 2014 after selling out during the quarter.
Essex Investment Management sold 1,690 Viracta Therapeutics, Inc. Common Stock shares in Q4 2014, an estimated $2.53M.
Essex Investment Management first reported a position in Viracta Therapeutics, Inc. Common Stock in Q3 2013 and held it in 5 quarters.
Essex Investment Management's Viracta Therapeutics, Inc. Common Stock position peaked at $2.53M in Q3 2014.
78 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q4 2014.

Based on Essex Investment Management's 13F filing for Q4 2014, filed 27 Jan 2015.